Ono Pharmaceutical 将来の成長

Future 基準チェック /06

Ono Pharmaceuticalの収益は年間10.2%で減少すると予測されていますが、年間収益は年間0.5%で増加すると予測されています。EPS は年間減少すると予測されています。自己資本利益率は 3 年後に8.2% 9.7%なると予測されています。

主要情報

-10.2%

収益成長率

-9.7%

EPS成長率

Pharmaceuticals 収益成長	21.6%
収益成長率	0.5%
将来の株主資本利益率	8.2%
アナリストカバレッジ	Good
最終更新日	12 Aug 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

MUN:ON4 - アナリストの将来予測と過去の財務データ ( )JPY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	515,323	78,336	75,181	117,258	9
3/31/2026	511,287	77,434	62,440	104,903	10
3/31/2025	480,057	74,657	-135,369	27,300	10
6/30/2024	500,331	120,953	105,249	121,111	N/A
3/31/2024	502,672	127,977	89,831	110,660	N/A
12/31/2023	498,070	127,611	91,301	106,044	N/A
9/30/2023	489,199	124,875	97,371	115,354	N/A
6/30/2023	460,481	115,064	98,429	116,894	N/A
3/31/2023	447,187	112,723	145,113	159,610	N/A
12/31/2022	428,951	111,555	137,391	149,495	N/A
9/30/2022	403,985	96,568	93,387	102,437	N/A
6/30/2022	380,720	85,922	78,395	88,151	N/A
3/31/2022	361,361	80,519	49,552	61,829	N/A
12/31/2021	345,781	73,558	38,233	53,343	N/A
9/30/2021	332,887	81,866	60,412	83,032	N/A
6/30/2021	321,734	78,003	47,401	70,321	N/A
3/31/2021	309,284	75,425	53,684	73,977	N/A
12/31/2020	302,054	74,364	53,088	72,011	N/A
9/30/2020	293,886	66,737	55,742	70,596	N/A
6/30/2020	293,351	64,870	58,824	78,232	N/A
3/31/2020	292,420	59,704	51,712	74,157	N/A
12/31/2019	290,736	60,233	43,202	73,947	N/A
9/30/2019	293,247	55,510	38,797	66,058	N/A
6/30/2019	291,374	52,633	32,152	58,850	N/A
3/31/2019	288,634	51,539	37,172	66,774	N/A
12/31/2018	284,463	51,978	42,500	67,269	N/A
9/30/2018	284,785	57,919	29,645	61,700	N/A
6/30/2018	272,165	53,746	16,591	48,716	N/A
3/31/2018	261,836	50,284	N/A	15,727	N/A
12/31/2017	256,522	54,760	N/A	28,754	N/A
9/30/2017	248,517	53,884	N/A	40,205	N/A
6/30/2017	246,953	53,887	N/A	53,650	N/A
3/31/2017	244,797	55,793	N/A	74,450	N/A
12/31/2016	236,710	48,270	N/A	44,743	N/A
9/30/2016	207,707	36,225	N/A	32,972	N/A
6/30/2016	183,345	29,206	N/A	16,805	N/A
3/31/2016	160,284	24,979	N/A	12,842	N/A
12/31/2015	140,927	16,449	N/A	29,716	N/A
9/30/2015	143,697	21,568	N/A	31,169	N/A
6/30/2015	139,663	19,521	N/A	30,488	N/A
3/31/2015	135,775	12,976	N/A	31,579	N/A
12/31/2014	137,592	17,663	N/A	N/A	N/A
9/30/2014	133,926	13,474	N/A	19,681	N/A
6/30/2014	137,146	16,787	N/A	N/A	N/A
3/31/2014	143,247	20,350	N/A	28,422	N/A
12/31/2013	145,946	21,574	N/A	N/A	N/A
9/30/2013	145,984	23,205	N/A	18,773	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ON4の収益は今後 3 年間で減少すると予測されています (年間-10.2% )。

収益対市場: ON4の収益は今後 3 年間で減少すると予測されています (年間-10.2% )。

高成長収益: ON4の収益は今後 3 年間で減少すると予測されています。

収益対市場: ON4の収益 ( 0.5% ) German市場 ( 5.6% ) よりも低い成長が予測されています。

高い収益成長: ON4の収益 ( 0.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ON4の自己資本利益率は、3年後には低くなると予測されています ( 8.2 %)。

Ono Pharmaceutical 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Ono Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 03, 2025

Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Full year 2024 earnings released: EPS: JP¥267 (vs JP¥231 in FY 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

Upcoming dividend of JP¥40.00 per share

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings released: EPS: JP¥88.30 (vs JP¥67.30 in 2Q 2023)

Less than half of directors are independent

Upcoming dividend of JP¥40.00 per share at 2.8% yield

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

First quarter 2024 earnings released: EPS: JP¥65.16 (vs JP¥60.37 in 1Q 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.

Now 23% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings released: EPS: JP¥231 (vs JP¥162 in FY 2022)

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

Now 25% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘